Marketed products
Vectura receives royalty income from its pharmaceutical company partners in respect of its portfolio of eight revenue-generating, marketed products, comprising both respiratory and non-respiratory. This income is used to help to offset the cost of Vectura's own pre-clinical and clinical stage product develoment programmes.
